NCT03324581: The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder |
|
|
| Completed | 2 | 239 | US | OPC-64005, Atomoxetine, Placebo | Otsuka Pharmaceutical Development & Commercialization, Inc. | Adult Attention Deficit Hyperactivity Disorder | 10/18 | 10/18 | | |
NCT04244253: A Phase 2 Trial of OPC-64005 for Major Depressive Disorder |
|
|
| Completed | 2 | 273 | Japan | OPC-64005 20 mg , Once-daily, OPC-64005 10 mg , Once-daily, Placebo, Once-daily | Otsuka Pharmaceutical Co., Ltd. | Major Depressive Disorder | 02/22 | 02/22 | | |
